Clinical Trial Highlights – GLP-1 agonists

McFarthing, Kevin; Larson, Danielle; Simuni, Tanya

doi:10.3233/jpd-200002

Cited by 13 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The status of the GM 608 phase II trial shows completed in subject recruitment, but no published data is available ( Table 1 ) (NCT01850381). NLY01 is a novel exenatide-based compound developing by Neuraly Inc. [ 129 ]. The NLY01 is a pegylated form of exendin-4 (exenatide), which binds to glucagon-like peptide-1 receptors (GLP-1R) and expresses in glial brain cells [ 129 ].…”

Section: Pd Therapeutic Strategies In Clinical Trialsmentioning

confidence: 99%

“…NLY01 is a novel exenatide-based compound developing by Neuraly Inc. [ 129 ]. The NLY01 is a pegylated form of exendin-4 (exenatide), which binds to glucagon-like peptide-1 receptors (GLP-1R) and expresses in glial brain cells [ 129 ]. Studies of NLY01 in PD showed that NLY01 limited neuronal death decreased formation of an inflammatory cascade and neurotoxic astrocytes, and partial motor function decline [ 129 ].…”

Section: Pd Therapeutic Strategies In Clinical Trialsmentioning

confidence: 99%

“…The NLY01 is a pegylated form of exendin-4 (exenatide), which binds to glucagon-like peptide-1 receptors (GLP-1R) and expresses in glial brain cells [ 129 ]. Studies of NLY01 in PD showed that NLY01 limited neuronal death decreased formation of an inflammatory cascade and neurotoxic astrocytes, and partial motor function decline [ 129 ]. NLY01 is in a phase II trial; the status is under recruitment which is developing by Neuraly, and they estimate to complete it by December 2022 ( Table 1 ) (NCT04154072).…”

Section: Pd Therapeutic Strategies In Clinical Trialsmentioning

confidence: 99%

See 2 more Smart Citations

Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update

Prasad

Hung

2021

Pharmaceuticals

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that currently has no cure, but treatments are available to improve PD symptoms and maintain quality of life. In 2020, about 10 million people worldwide were living with PD. In 1970, the United States Food and Drug Administration approved the drug levodopa as a dopamine replacement to manage PD motor symptoms; levodopa-carbidopa combination became commercialized in 1975. After over 50 years of use, levodopa is still the gold standard for PD treatment. Unfortunately, levodopa therapy-induced dyskinesia and OFF symptoms remain unresolved. Therefore, we urgently need to analyze each current clinical trial’s status and therapeutic strategy to discover new therapeutic approaches for PD treatment. We surveyed 293 registered clinical trials on ClinicalTrials.gov from 2008 to 16 June 2021. After excluded levodopa/carbidopa derivative add-on therapies, we identified 47 trials as PD treatment drugs or therapies. Among them, 19 trials are in phase I (41%), 25 trials are in phase II (53%), and 3 trials are in phase III (6%). The three phase-III trials use embryonic dopamine cell implant, 5-HT1A receptor agonist (sarizotan), and adenosine A2A receptor antagonist (caffeine). The therapeutic strategy of each trial shows 29, 5, 1, 5, 5, and 2 trials use small molecules, monoclonal antibodies, plasma therapy, cell therapy, gene therapy, and herbal extract, respectively. Additionally, we discuss the most potent drug or therapy among these trials. By systematically updating the current trial status and analyzing the therapeutic strategies, we hope this review can provide new ideas and insights for PD therapy development.

show abstract

Section: Pd Therapeutic Strategies In Clinical Trialsmentioning

confidence: 99%

Section: Pd Therapeutic Strategies In Clinical Trialsmentioning

confidence: 99%

Section: Pd Therapeutic Strategies In Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update

Prasad

Hung

2021

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Hence, the half life of GLP1 analogue ranges from1 to 2 minutes. Synthetic analogues of GLP 1 (exenatide, liraglutide, albiglutide, taspoglutide, lixisenatide, dulaglutide) are relatively resistant to degradation by DPP4 [7].…”

Section: Glucagon-like Peptide 1 (Glp1) Receptor Agonistsmentioning

confidence: 99%

Comparative Review of Drugs Used in Diabetes Mellitus—New and Old

Haq¹,

Siraj²,

Ameer³

et al. 2021

JDM

View full text Add to dashboard Cite

Background: Diabetes mellitus (DM) is a syndrome of chronically elevated glucose level in the blood either due to insulin resistance, insulin deficiency or both. In addition, it may occur due to defective metabolism of carbohydrates, fats and proteins. There are 3 main types of DM: Type 2 DM is more prevalent in adults and is typically due to relative insulin deficiency, deficiency of insulin in children leads to DM type 1; and lastly, gestational diabetes occurs during pregnancy resulting from an imbalance of placental hormones. Introduction: Insulin, Biguanides and Sulfonylureas are some of the drug classes used to treat DM. However, their use is complicated by numerous side effects, such as; hypoglycemia & weight gain from insulin and sulfonylureas; lactic acidosis, vitamin B12 deficiency and gastrointestinal upset with metformin. Route of administration and cost are also important factors to consider when prescribing. It is for this reason the quest for newer, safer and easier to administer drugs is ongoing. Methodology: Used all the articles available on anti Diabetic drugs on web especially in British Medical Journal, Elsevier, Pubmed, Google scholar and Wikipedia etc. Got a final review article to compare the older and newer anti Diabetic drugs. Results and Conclusion: Insulin is good for controlling acute hyperglycemic states in DM but it causes acute hypoglycemia and lipodystrophy. Metformin is good hypoglycemic and easily available but causes hypoglycemia, metallic taste, Lactic acidosis and B12 deficiency. Sulfonylureas are good hypoglycemic but causes severe hypoglycemia acutely and weight gain so contraindicated for obese or How to cite this paper:

show abstract

“…Furthermore, the pathogenesis of PD is highly complex, involving damaging effects due to protein aggregation, inflammation, mitochondrial dysfunction, impaired autophagy and reactive oxygen species just to mention a few [ 2 ], and it may be naive to think that a single molecule can halt this multitude of deleterious processes. It is thought-provoking that the drugs which are currently showing most promising disease-slowing effects in clinical trials are GLP-1 agonists, which have an unclear mechanism of action proposed to involve modulation of several cell types including neurons, glia and immune cells [ 3, 4 ]. While refined and efficacious disease-modifying treatments are still struggling to reach the market, patients are in dire need of therapies which provide better quality of life and which are effective beyond the initial period after diagnosis.…”

Section: Introduction: Why Do We Need Advanced Regenerative Therapies For Parkinson’s Disease?mentioning

confidence: 99%

Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

Tomishima¹,

Kirkeby

2021

JPD

View full text Add to dashboard Cite

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

show abstract

Clinical Trial Highlights – GLP-1 agonists

Cited by 13 publications

References 6 publications

Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update

Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update

Comparative Review of Drugs Used in Diabetes Mellitus—New and Old

Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

Contact Info

Product

Resources

About